AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank in a research report issued to clients and investors on Wednesday, MarketBeat.Com reports. They presently have a GBX 5,600 ($80.65) target price on the biopharmaceutical company’s stock. Deutsche Bank’s price target suggests a potential upside of 42.57% from the […]
